Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jul;202(2):284-288.
doi: 10.1111/bjh.18853. Epub 2023 May 14.

Combination of azacitidine, venetoclax and ruxolitinib in blast phase myeloproliferative neoplasms

Thomas Systchenko  1 , Jean-Claude Chomel  2 , Pilar Gallego-Hernanz  1 , Niels Moya  1 , Déborah Desmier  1 , Natacha Maillard  1 , Arthur Bobin  1 , Mathilde Vonfeld  1 , Hélène Gardeney  1 , Emilie Cayssials E  1 , José Torregrosa  1
Affiliations

Combination of azacitidine, venetoclax and ruxolitinib in blast phase myeloproliferative neoplasms

Thomas Systchenko et al. Br J Haematol. 2023 Jul.

Abstract

Myeloproliferative neoplasms in blastic phase (MPN-BP) have a dreadful prognosis. We report the characteristics and outcomes of five MPN-BP patients treated with a never-before-described combination of azacytidine and venetoclax (to control BP transformation), added to ruxolitinib (needed to control constitutional symptoms). Median age was 76 years (range 72-84), and worst performance status was 2. The overall response rate was 80%, and the complete remission rate was 40%. With median follow-up of 10.0 months (range 4.2-13.4), median overall survival was 13.4 months (95% CI 4.2-13.4). We did not detect any unexpected treatment-related toxicity, and quality of life was improved.

Keywords: azacitidine; blast phase myeloproliferative neoplasms; ruxolitinib; venetoclax.

PubMed Disclaimer

References

REFERENCES

    1. Dunbar AJ, Rampal RK, Levine R. Leukemia secondary to myeloproliferative neoplasms. Blood. 2020;136(1):61-70.
    1. DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383(7):617-29.
    1. Mascarenhas JO, Rampal RK, Kosiorek HE, Bhave R, Hexner E, Wang ES, et al. Phase 2 study of ruxolitinib and decitabine in patients with myeloproliferative neoplasm in accelerated and blast phase. Blood Adv. 2020;4:5246-56.
    1. Gerds AT, Gotlib J, Ali H, Bose P, Dunbar A, Elshoury A, et al. Myeloproliferative neoplasms, version 3.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2022;20(9):1033-62.
    1. Cheson BD, Bennett JM, Kopecky KJ, Büchner T, Willman CL, Estey EH, et al. International Working Group for Diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol. 2003;21(24):4642-9.

LinkOut - more resources